Section 5

REFERENCES
REFERENCES


42. CDER: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. 2000


63. Dasgupta A & McLemore JL: Elevated free phenytoin and free valproic acid concentrations in sera of patients infected with human immunodeficiency virus. Ther Drug Monit 1998; 20:63-67


186. Michelucci R. Cipolla G., Passarelli D. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. Epilepsia 1996; 37: 1107-1110


232. Product Information; Biaxin Filmtab 250mg and 500mg and Biaxin XL 500mg. Mfd. by Abbott Laboratories PR Ltd., Barceloneta, PR 00617. Biaxin Granules for Oral Suspension, 125mg/5mL and 250mg/5mL. Mfd. by Abbott Laboratories, North Chicago, IL 60064. For Abbott Laboratories, North Chicago, IL 60064, U.S.A. Revised: January, 2005


264. Sampliner R, Iber FL: Diphenylhydantoin Control of Alcohol Withdrawal Seizures. Results of a Controlled Study. JAMA 1974; 230(10):1430-1432,


305. Tsai b, Jing-Jane, MD, Lai Ming-Liang, MD, Yang Yea-Huei Kao, BS and Huang Jing-Ding, PhD. Comparison on Bioequivalence of Four Phenytoin Preparations in patients with Multiple-Dose Treatment. J. Clin. Pharmacol. 1993; 32: 272-276


328. Woodbury DM. Role of pharmacological factors in the evaluation of anticonvulsant drugs. Epilepsia. 1969; 10(2): 121-44

